News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A 36-week, randomized, double-blind, placebo controlled, parallel group trial to assess the efficacy and safety of PXL065 versus placebo in noncirrhotic, biopsy-proven Nonalcoholic Steatohepatitis (NASH) patients

Please contact us for more information or to learn if you are eligible to participate.

© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram